ZLAB N Stock Overview
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Zai Lab Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$271.00 |
| 52 Week High | US$648.41 |
| 52 Week Low | US$270.64 |
| Beta | 1.12 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -89.47% |
| 5 Year Change | n/a |
| Change since IPO | -81.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZLAB N | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how ZLAB N performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how ZLAB N performed against the MX Market.
Price Volatility
| ZLAB N volatility | |
|---|---|
| ZLAB N Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: ZLAB N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ZLAB N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 2,175 | Samantha Du | www.zailaboratory.com |
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients.
Zai Lab Limited Fundamentals Summary
| ZLAB N fundamental statistics | |
|---|---|
| Market cap | Mex$26.73b |
| Earnings (TTM) | -Mex$5.73b |
| Revenue (TTM) | Mex$4.57b |
5.8x
P/S Ratio-4.7x
P/E RatioIs ZLAB N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZLAB N income statement (TTM) | |
|---|---|
| Revenue | US$266.72m |
| Cost of Revenue | US$361.68m |
| Gross Profit | -US$94.96m |
| Other Expenses | US$239.66m |
| Earnings | -US$334.62m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -3.39 |
| Gross Margin | -35.60% |
| Net Profit Margin | -125.46% |
| Debt/Equity Ratio | 0% |
How did ZLAB N perform over the long term?
See historical performance and comparison